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MTTAbstract The use of doxorubicin (DOX) is limited by its dose-dependent cardiotoxicity.
Entrapped DOX in liposome has been shown to reduce cardiotoxicity. Results showed that about
92% of the total drug was encapsulated in liposome. The release experiments showed a weak DOX
leakage in both culture medium and in PBS, more than 98% and 90% of the encapsulated DOX
respectively was still retained in liposomes after 24 h of incubation. When the release experiments
were carried out in phosphate buffer pH5.3, the leakage of DOX from liposomes reached 37% after
24 h of incubation. Evaluation of cellular uptake of the liposomal DOX indicated the possible endo-
cytosis of liposomes because the majority of visible ﬂuorescence of DOX was mainly in the cyto-
plasm, whereas the nuclear compartment showed a weak intensity. When using unloaded
ﬂuorescent-liposomes, the ﬂuorescence was absent in nuclei suggests that liposomes cannot cross
the nuclear membrane. MTT assay and measurement of LDH release suggest that necrosis is the
form of cellular death predominates in H9c2 cells exposed to high doses of DOX, while for weak
doses apoptosis could be the predominate form. Entrapped DOX reduced signiﬁcantly DOX toxi-
city after 3 and 6 h of incubation, but after 20 h entrapped DOX is more toxic than free one.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
DOX is one of the most efﬁcient anticancer drugs used against
solid tumors and hematological malignancies (Hrelia et al.,
2002); however, its side effects, in particular its cardiotoxicity,
limit its use (Rahman et al., 2007). The mechanisms implicated
in cardiotoxicity and cytotoxicity are different. The antineo-
plastic mechanism of DOX has been attributed to intercalation
of the planar anthracycline ring into the DNA helix and/or
covalent binding to proteins involved in DNA replication
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generation of reactive oxygen species has been proposed to
be responsible for the cardiotoxicity of DOX (Alyane et al.,
2008). This difference in mechanisms suggests that the acute
and chronic toxicities associated with DOX could be reduced
and higher doses could be used if the drug could be more efﬁ-
ciently targeted to cancer cells, for example, by encapsulation
in liposomes.
Liposomes, unilamellar or multilamellar lipid vesicles
(Santra and Mukherjee, 2009), are well established as drug
delivery systems for low molecular weight molecules; when
administrated intravenously, may improve the therapeutic
index of some drugs due to the EPR (enhanced permeability
and retention) effect (Zuker et al., 2009). The accumulation
of liposomes in tumors is favored not only by a leaky
microvasculature but also by an insufﬁcient lymphatic
drainage. The combination of these two factors is referred to
as the ‘‘EPR phenomenon’’ (Minotti et al., 2004).
Liposomal formulations of DOX have been studied for a
number of years as a means of reducing the cardiac toxicity
of the drug because liposomal encapsulation would be
expected to shift DOX away from myocardial tissue (with a
normal endothelial barrier), while maintaining tumor exposure
(Rahman et al., 2007). Furthermore, encapsulation of DOX
within long-circulating liposomes decorated with poly(ethylene
glycol) (PEG liposomes), reduces its uptake by the reticulo-
endothelial system and prolongs its serum half-life to around
50 h compared with 10 min for the free drug (Berry et al.,
1998). As a result, DOX in PEG liposomal has been shown
to have an increased therapeutic efﬁcacy and reduced car-
diotoxicity compared to free DOX (Gabizon et al., 2003)
and a commercial formulation is marketed as Doxil or
Caelyx (Janssen Pharmaceuticals).
In order to achieve a high yield of DOX encapsulation in
liposomes a remote loading approach is used (Ogawara
et al., 2009). The method involves the addition of drug to pre-
formed liposomes through a pH gradient or an ion gradient
capable of generating a pH gradient (Mayer et al., 1990).
Due to their high payload of drug, liposomal systems are the
best method to passively target anthracyclines to tumors,
compared with microspheres or nanoparticles (Minotti et al.,
2004).
Although the distribution of liposomal DOX in the body
has been extensively studied, less work has been done on its
interaction with cardiac cells. The objective of this work was
to encapsulate DOX in PEG liposomes, investigate the mecha-
nism of interaction between these liposomes and H9c2 cells
using ﬂow cytometry and confocal microscopy and assess the
consequences for cell viability using well established tests.2. Material and methods
2.1. Preparation of PEG liposomes
Pegylated liposomes, composed with HEPC (Hydrogenated
Egg Yolk Phosphatidylcholine), CHOL (Cholesterol) and
DSPE-PEG2000 (Methoxypolyetheleneglycol (Mw 2000)-dis-
tearylphosphatidylethanolamine) (185:1.00:015, molar ratio),
were prepared as previously described by Zucker et al.
(2009). Brieﬂy, the lipids were dissolved in chloroform, and
after evaporation of the organic solvent with rotary evaporator(Bu¨chi Rotavapor R-215, Switzerland) under reduced pressure
at room temperature. The resulting lipid ﬁlm was hydrated
at 70 C in 250 mM ammonium sulfate (pH5.4) to form
multilamellar vesicles (MLV). The liposome size was reduced
by stepwise extrusion in two steps, ﬁrstly through 0.2 lm
and then through 0.1 lm pore-diameter polycarbonate ﬁlters
(Whatman, Maidstone, Kent, UK). Each extrusion step was
performed 5–10 times at 70 C using a high-pressure extruder
(Northern Lipids, Inc. Burnaby, BC, Canada).
The mean diameters of the resulting liposomes were deter-
mined by photon correlation spectroscopy (PCS) on a Malvern
Zetasizer (Zetasizer Nano ZS Zen 3600, Malvern instruments,
UK) at 25 C, using water as the dispersant. Three measure-
ments were taken on each sample.
In the aim to study interaction between liposomes and
H9c2 cells, ﬂuorescent liposomes were prepared following
the same steps but with the addition of 1% of Rhodamine
B-DHPE (Sigma) to the lipid mixture.2.2. DOX loading
DOX (Chemos GmbH, Germany) was loaded into preformed
liposomes via a transmembrane pH gradient method and the
free DOX was removed by gel ﬁltration. Brieﬂy, the liposomal
suspension, prepared as described above, was passed through a
Sephadex G25 gel-ﬁltration column (PD-10 Desalting
Columns, GE Healthcare Ltd, Sweden) pre-equilibrated by
PBS pH7.4 to remove the ammonium sulfate solution. Then,
a solution of DOX (10 mg/mL) was added at pH 7.4 to create
a transmembrane PH gradient (drug to lipid ratio 1/20 w/w).
This suspension was stirred for 1 h at 60 C. Subsequently,
unloaded DOX was removed by Sephadex G25 column pre-
equilibrated with PBS pH7.4.
The amount of encapsulated DOX in PEG liposomes
(DOXEnc) was determined by measuring absorption at
483 nm using UV–visible spectrophotometer (Uvikon 930,
Kontron Instruments, Germany) after lysis of the liposomes
with 10% SDS (w/v) (Mayer et al., 1990).
Drug encapsulation efﬁciency (EE%) was calculated as
follows:
EE% ¼ DOXEnc
DOXTot
 
 1002.3. DOX release
The in vitro DOX release from liposomes was studied in PBS
pH7.4, in complete Dulbecco’s modiﬁed Eagle’s medium
(DMEM) (supplemented with 10% of fetal bovine serum
(FBS), 100 U/mL penicillin and 100 lg/mL streptomycin)
and in phosphate buffer at pH5.3. 200 ll of the DOX-loaded
liposome suspension was dispersed within a vial containing
2.0 mL of PBS, phosphate buffer and DMEM, protected from
light and stirred gently at 37 C. At predetermined time inter-
vals, the entire release medium was subjected to ultracen-
trifugation at 300,000 g for 12 h at 4 C (Beckman Coulter
Optima L.90 K Ultracentrifuge). The concentration of released
and retained DOX was evaluated in the supernatant and in the
pellet respectively using UV spectrophotometry at 483 nm. A
calibration curve was constructed using different concentra-
tions of free DOX in PBS, DMEM and phosphate buffer.
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gated by recording the UV–visible absorbance spectra of free
and encapsulated DOX in PBS, phosphate buffer and in
DMEM.
2.4. Absorption spectra
To verify the inﬂuence of different solvents on the stability of
DOX structure, absorption spectra were recorded using a
Spectroscopy System (cell path length = 1.00 cm). DOX was
added to buffers at pH 7.4 (PBS), pH 7.4 (complete DMEM
medium) and pH 5.39 (phosphate buffer).2.5. Cell culture
H9c2 cells, CRL 1446 (the rat embryonic ventricular myocar-
dial cell line) were obtained from the American Type Culture
Collection. The cells were cultured and maintained in complete
DMEM at 37 C in a humidiﬁed incubator with 5% CO2. Cells
were subcultured at a 1:4 ratio every 3 days after detachment
with trypsin. For MTT and LDH assays, the cells were plated
in 96-well plates (TPP Tissue culture dishes, Switzerland) at a
density of 10000 cells per well and incubated overnight to
allow cell attachment.-0,5
0
0,5
1
1,5
2
2,5
3
300 400 500
Absorbance DOX (
DOX (
DOX (
0
0,5
1
1,5
2
2,5
3
3,5
4
180 280 380 48
Absorbance
(a)
(b)
Figure 1 UV/visible spectra of free and entrapped DOX and empty
with different pH. No noticeable differences in the obtained absorb
indicate the absence of absorbance of lipid at 483 nm. The resemblanc
presence of drug in the loaded liposomes.2.6. MTT assay
The MTT assay (Mosmann, 1983) was used to estimate the
cytotoxicity of free DOX, encapsulated DOX and empty lipo-
somes toward H9c2 cells. Cells were incubated with increasing
concentration of each compound at concentration ranging
between 1 and 80 lM, in triplicate. Untreated cells were used
as controls. The cells were exposed for 48 h in a 5% CO2
incubator at 37 C. After incubation, 20 ll MTT (Sigma)
(5 mg/mL) solution was added in all wells, except in one well
that served as blank, and incubated at 37 C for 4 h. Finally,
the medium was removed and formazan salt crystals were dis-
solved by addition of 200 ll of dimethylsulfoxide (Biobasic
INC) to all wells. Plates were analyzed in an ELISA plate
reader (Labsystems multiskan RS-232C, Finland) at 570 nm.
Cell viability was deﬁned relative to untreated control cells
as follows:
Cell viability¼ absorbance of treated sample=absorbance of control:2.7. LDH assay
The LDH cytotoxicity detection kit (Roche Diagnostics
GmbH, Mannheim, Germany) was used according to the600 700 800
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Figure 2 In-vitro release of DOX from liposomes in complete cell culture media DMEM (a), in PBS pH7.4 (b) and in phosphate buffer
pH5.3 (c). 200 ll of liposome suspension was diluted in 2 ml of the medium and placed in a vial, protected from light and stirred gently at
37 C. At various time points, the amount of DOX released was estimated in the pellet and supernatant after ultracentrifugation by UV–
vis spectroscopy at 483 nm.
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tion of LDH activity released from the cytosol of damaged
cells into the medium, thus indicating cell membrane damage.
Cells were incubated under the same conditions as for the
MTT assay described above. LDH released into the extra-
cellular medium of cells treated with different concentrations
of free DOX, DOX-loaded liposomes and empty liposomes
was expressed as a percentage of the total LDH activity in
the cells [% of LDH released = extracellular LDH/(extra-
cellular LDH+ intracellular LDH)].
2.8. Analysis of cellular uptake of DOX by ﬂow cytometry
Flow cytometry studies were conducted to compare free
DOX, lipo-DOX, and empty ﬂuorescent liposome uptakeby H9c2 cells. H9c2 cell plated in two 6-well plates (TPP
Tissue culture dishes, Switzerland) at a density of 200,000
cells per well and incubated for 24 h. Then cells were
exposed to free or encapsulated DOX (20 lM, ﬁnal concen-
tration) or to the empty ﬂuorescent liposomes. Untreated
cells were used as negative control. After 3 or 20 h, the
medium of each well was removed and the cells were then
washed three times with 2 mL of PBS (pH7.4), harvested
using 0.5% EDTA/trypsin and diluted in small volume of
PBS. Finally, cells were examined by ﬂow cytometry using
a FACSCalibur (Becton Dickinson, USA). Cell-associated
DOX or rhodamine was excited with an argon laser
(488 nm) and ﬂuorescence was detected at 585 nm (FL2
ﬁlter). 10,000 gated events were collected and analyzed with
the CellQuest software.
A1 B1
A2
B3
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Figure 3 Flow cytometry measurements of DOX uptake by H9c2 cells after 3 h (left panel) and 20 h (right panel) of incubation with
entrapped DOX (A2, B2) empty ﬂuorescent liposomes (A3, B3). Untreated cells served as negative control (A1, A2), free DOX was used as
positive control (A4, B4). These graphs show the ﬂuorescence intensity on the x-axis and the number of cells with this level of ﬂuorescence
on the y-axis.
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Table 1 Uptake of liposomal DOX in H9c2 cells derived from
ﬂow cytometry measurements (arbitrary units).
Fluorescence intensity
after 3 h
Fluorescence intensity
after 20 h
Free DOX 175 ± 61 273 ± 99
Entrapped
DOX
133 ± 39 129 ± 38
Empty
liposomes
19 ± 34 170 ± 89
Untreated
cells
13 ± 12 13 ± 5
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Confocal ﬂuorescent microscopy was also used to compare the
uptake of free and encapsulated DOX and the uptake of empty
ﬂorescent liposomes and investigate their cellular distribution.
Cells were grown in 6 well plates on glass coverslips (40,000
cells per mL). After 24 h, cells were treated free and encapsu-
lated DOX (10 lM ﬁnal concentration) and with empty ﬂores-
cent liposome’s, then incubated for 3 or 20 h at 37 C. After
incubation, cells were washed two times with cold PBS
(pH7.4), ﬁxed in formaldehyde 4% (in PBS) with
Hoechst33342 stain (1 lg/mL) for 3 h. Fluorescent images of
cells were acquired using a LSM 510 Zeiss confocal microscope
(Carl Zeiss, Jena, Germany) at excitation and emission wave-
lengths of 543 nm and 560 nm respectively.
3. Results
3.1. Preparation and characterization of liposomes
In this work, we used the extrusion method to generate
monodisperse populations of unilamellar vesicles (Fenske
and Cullis, 2007). Whatever the preparation, the mean particle
diameter was 110 nm with a polydispersity index was 0.046.
DOX loading efﬁciency obtained by the transmembrane pH
gradients procedure was found to be greater than 90% at the
drug-to-lipid ratio of 1:20 (w/w) used in this study. Final
drug-to-lipid ratio was in excess of 1/2 (mol/mol). This high
level of EE can be explained by the formation of an insoluble
drug precipitate inside liposomes (Li et al., 2000).
3.2. Chemical stability of the entrapped DOX
The chemical stability of the drug in different solvents was
investigated by recording the UV–visible absorbance spectra
(Fig. 1a). There were no noticeable differences between the
absorbance spectra obtained in the different buffers (PBS
pH7.4, DMEM pH7.4, Phosphate Buffer pH5.3), suggesting
no signiﬁcant changes in the physical properties of the drug.
The UV–visible spectra of the free and encapsulated DOX
and empty liposomes are shown in Fig. 1b. The UV–visible
spectrum of empty liposomes clearly indicates the absence of
absorbance of lipid at 483 nm. The resemblance of the spectra
corresponding to free DOX and entrapped DOX conﬁrms the
presence of drug in the loaded liposomes (Chouhan and
Bajpai, 2009).
3.3. In-vitro release of DOX from liposomes
The proﬁles of DOX release from liposomes in vitro in PBS
pH7.4, DMEM and phosphate buffer pH5.3 are presented in
Fig. 2. The release of the entrapped DOX was very weak
and similar in culture medium (Fig. 2a) and in PBS
(Fig. 2b) very little encapsulated DOX was released and more
than 98% and 90% respectively of the encapsulated DOX was
retained in liposomes after 24 h of incubation at 37 C; In con-
trast, in phosphate buffer pH5.3 (Fig. 2c), DOX release from
liposomes reached 37% after 24 h of incubation. Thus, only a
small amount of drug was be released at physiological pH,
while more efﬁcient release was observed in acidic conditions.It is possible that the acidic pH destabilizes the lipid carrier
(Minotti et al., 2004) but it has also been suggested that the
physical state of DOX plays a role in drug release (Li et al.,
2000). The results suggest that liposomes would be able to
retain their cargo of DOX in the plasma but release it in the
endosomes after capture by cells (Barenholz, 2001).
3.4. Cellular uptake of DOX by ﬂow cytometry
The ﬂuorescent properties of DOX were used to investigate its
uptake by the cardiac cells when it was presented as free drug
or as liposomes, by ﬂow cytometry experiments. Empty lipo-
somes labeled with a ﬂuorescent lipid were used to study the
interaction of the carrier with the cells. The results are shown
in Fig. 3. Fig. 3A1 and B1 shows the background ﬂuorescence
of untreated cells at 3 h and 20 h, respectively. Treatment with
free DOX (Fig. 3A4 and B4) led to a high level of cell-associ-
ated ﬂuorescence, particularly after 20 h (ﬂuorescence intensity
of 175 arbitrary units after 3 h and 273 after 20 h, as compared
with about 13 units in the control cells at either time, Table 1).
When the same concentration of DOX was incubated with the
cells in the form of liposomes (Fig. 3A2 and B2) the mean ﬂuo-
rescence intensity was lower than that of free DOX (133 arbi-
trary units after 3 h and 129 after 20 h). The interaction of the
liposomes themselves with the cells was determined using rho-
damine labeled empty liposomes (Fig. 3A3 and B3). The ﬂuo-
rescence intensity was only slightly higher than the untreated
cells at 3 h, but increased after 20 h, suggesting a gradual accu-
mulation of the PEG-liposomes within the cells. However, it is
not possible to make direct comparisons between the empty
liposomes and the DOX-loaded ones because the properties
of the ﬂuorophores are different. The uptake of DOX in
H9c2 cells treated with encapsulated DOX was not a result
of release of DOX from liposomes, because the DOX release
in DMEM was very weak, as shown in Fig. 2. However,
DOX-loaded liposomes may interact more with cells than
empty liposomes because of their increased density.
The uptake of free DOX by the cells was accompanied by
an increase in cell debris, which increased from 2% of the total
ﬂuorescence intensity at 3 h to 23% at 20 h.
3.5. Intracellular uptake and distribution of DOX by confocal
microscopy analysis
Confocal microscopy was used as a complement to ﬂow
cytometry, to examine liposome–cell interactions in more
detail. Phase contrast images of H9c2 cells adhering to glass
Figure 4 Confocal microscopy images of H9c2 cells treated with free and entrapped DOX. Images A and B show the phase-contrast
appearance of untreated cells after 3 h and 20 h of incubation respectively. Images C and D show cells incubated with free DOX for 3 h
and 20 h respectively. Images E and F depict cells incubated with entrapped DOX for 3 h and 20 h respectively.
Remote loading of doxorubicin into liposomes 171coverslips and incubated for 3 h and 20 h are shown in
Fig. 4A and B respectively. Fig. 4C and D shows the results
of incubation with free DOX for 3 h and 20 h respectively.
Intense ﬂuorescence can be observed in the nucleus, with only
diffuse staining in the cytoplasm. When encapsulated DOX
was used at the same concentration (Fig. 4E and F) the
nuclear ﬂuorescence was much less intense.
Fig. 5 shows the results of incubation with rhodamine-
labeled liposomes. Phase contrast images of untreated cellsare shown in Fig. 5A and D (3 h and 20 h incubation respec-
tively). Treatment with unloaded liposomes did not affect cell
morphology (results not shown). The accumulation of ﬂuores-
cence associated with the cells was slow (compare images B
and C, recorded after 3 h, and images E and F, recorded after
20 h). Furthermore, the ﬂuorescence was limited to the
cytoplasm and the nuclei remained unstained. Thus, intact
liposomes are unable to cross the nuclear membrane and the
DOX observed in the nuclei in Fig. 4E and F was the result
Figure 5 Confocal images of H9c2 cells treated with unloaded ﬂuorescent liposomes. Phase-contrast images of untreated cells after 3 h
and 20 h of culture are shown in A and D respectively. Images B and C show cells treated with unloaded ﬂuorescent liposome for 3 h,
while E and F show cells after 20 h with the unloaded liposomes.
172 M. Alyane et al.of release from the liposomes, probably in the endosomes. The
observation that DOX release was increased at pH 5.3
(Fig. 2c) was consistent with this interpretation.
3.6. Cytotoxicity of free and liposome-encapsulated DOX
The effects of free and liposome-encapsulated DOX on the via-
bility of H9c2 cells were compared. Two well established tests
were used. The MTT test measures the activity of mitochon-
drial dehydrogenases and therefore reﬂects both cytostaticand cytotoxic effects. On the other hand, the release of the
cytosolic LDH enzyme evaluates membrane integrity and
thereby indicates cell death by necrosis (Bernuzzi et al., 2009;
Sarda˜o et al., 2009). The tests were performed after 48 h of
exposure to free or encapsulated DOX, which represents twice
the cell doubling time. The results are shown in Fig. 6.
In the MTT test, DOX showed a dose-dependent inhibition
of dehydrogenase activity, with an IC50 value of about 30 lM
(Fig. 6A). At concentrations of 30 lM and higher, the liposo-
mal form induced signiﬁcantly less inhibition than the free
Figure 6 Cytotoxicity of entrapped and free DOX was measured in H9c2 cells after 48 h of incubation, measured by two classical tests:
(A) MTT conversion; (B) LDH release. The results are expressed as a percentage of the value in untreated cells and are the mean ± SD of
four wells.
Remote loading of doxorubicin into liposomes 173drug (P> 5%, Student’s two-tailed t test). The effect of empty
liposomes at an equivalent concentration was always less than
that of the loaded liposomes; however some inhibition of
mitochondrial dehydrogenase activity was observed.
LDH release under the same conditions is shown in Fig. 6B.
Even at low concentrations, free DOX causes considerable
LDH leakage (around 80% for concentrations between 10
and 30 lM, rising to 100% for 50 and 80 lM). The LDH
release after treatment with encapsulated DOX was always
signiﬁcantly lower. LDH release provoked by empty liposomes
was quite similar to that provoked by loaded liposomes.
4. Discussion
For many years, drug delivery strategies have been developed
to improve the effectiveness and reduce the cardiotoxicity of
anthracyclines. In a ﬁrst approach, association with colloidalnanosystems such as liposomes and nanoparticles allows the
distribution to be modiﬁed avoiding the heart. In a second
step, carriers speciﬁcally directed toward cancer cells have been
developed (Barenholz, 2001).
For the ﬁrst strategy, liposomes have been the most fre-
quently studied carrier system and were therefore chosen for
the present work. Our results for DOX encapsulation are in
agreement with previous studies, showing that the use of a trans-
membrane pH gradient yields high trapping efﬁciency (Woodle,
1995; Fenske and Cullis, 2007; Ogawara et al., 2009) and
encapsulation close to 100% (Fenske and Cullis, 2007;
Ogawara et al., 2009). In our case more than 90% of added
DOXwas incorporated.This slightly lower value comparedwith
the literature can be explained by the difference in composition
of lipids entering in the structure of the liposomal membrane as
well as by the difference salts used for the generation of the
gradient of pH (Abraham et al., 2002; Fritze et al., 2006).
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liposome-encapsulated DOX is different from that of the free
drug, and this contributes to a reduction in toxicity to normal
tissues (Berry et al., 1998; Gabizon et al., 2003; Batist, 2007).
Our work focussed on the interactions between free and encap-
sulated drug and cardiac cells. Observations made by confocal
microscopy and ﬂow cytometry suggest that DOX-liposomes
can be taken up by these cells by endocytosis, despite the
presence of PEG on their surface. H9c2 cells treated with
empty ﬂuorescent liposomes displayed rhodamine ﬂuorescence
in a punctuate pattern in the cytoplasm (Fig. 5) and ﬂow
cytometry showed that the peak of ﬂuorescence shifted toward
higher values with increasing time of incubation (Fig. 3A3 and
B3). We were also able to use the intrinsic ﬂuorescence of DOX
to follow its uptake by cells. In confocal microscopy the ﬂuo-
rescence of the DOX, localized mainly in the nucleus, was
more intense in cells treated with the free DOX compared with
cells exposed for the same time to the same concentration in
liposomal form. This result was corroborated by the ﬂow
cytometry results and is in accordance with earlier observa-
tions (Morisco et al., 2011). The high afﬁnity of DOX for
DNA appears to be the major driving force for the drug to
enter cells by diffusion (Frezard and Garnier-Siullerot, 1991).
Confocal microscopy revealed that the ﬂuorescence of DOX
is mainly in the nuclear compartment while the cytoplasm
shows a weak intensity of ﬂuorescence (Xiong et al., 2005).
Administration of DOX to a sensitive cell line results in rapid
nuclear uptake, with >99.8% of nuclear drug becoming
directly associated with DNA (Cutts and Phillips, 1995). It
appears that endocytosis of the liposomes is slower and
therefore limits accumulation within the cells. However,
DOX ﬂuorescence inside these liposomes may be greatly
quenched (Lee and Low, 1995), and the cytoplasm may
contain signiﬁcantly more Lipo-DOX than indicated by their
relative ﬂuorescence intensity.
The measurement of in vitro drug release from the liposomes
enabled us to understand the mechanism of DOX uptake from
liposomes. Very little release was observed when the liposomes
were incubated in pH 7.4 buffer or in complete cell culture med-
ium for 24 h. Therefore, the DOX uptake seen when loaded
liposomes were incubated with the cells was probably due to
the uptake of intact liposomes rather than release into the
medium. This weak release of DOX from liposomes is the result
of their lipid composition (saturated phospholipid, choles-
terol). Both leakage and diffusion of drug across the cell
membrane after contact are limited (Hu et al., 1995). On the
other hand, more drug release was seen at pH5.3. Thus DOX
could have been released at the acid pH of the endosomes
and then enter the nucleus by diffusion. The pH of tumor
stroma has been reported to be lower than that of normal tissue
(Ganta et al., 2008), and therefore this pH-dependent release
could allow help to deliver the drug to tumor cells.
Cytotoxicity studies carried out after 48 h (two cell dou-
bling times) of exposure to free and liposome-encapsulated
DOX. The results (Fig. 6) showed that the toxicity of the
anthracycline was reduced by encapsulation. This could
probably be explained by the reduced uptake by the cells.
Therefore, the reduced cardiac toxicity of the encapsulated
drug, which leads to a better therapeutic index for antican-
cer treatment, can be attributed to lower uptake by cardiac
cells as well as an altered organ distribution of the drug.Acknowledgements
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